AIM
ELDN icon

Acrospire Investment Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Acrospire Investment Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-287
Closed -$46K – 2274
2016
Q4 		$46K Buy
287
+266
+1,267% +$51K 0.02% 1442
2016
Q3 		$5K Buy
+21
New +$7.68K ﹤0.01% 1818

Other funds holding ELDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Acrospire Investment Management's ELDN Position: Q1 2017 in Review

Acrospire Investment Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2017, closing a stake of 287 shares — an estimated $46K sold.

Acrospire Investment Management first reported a position in ELDN in Q3 2016 and held it in 2 quarters. The position peaked at $46K in Q4 2016. 34 funds tracked by Wall St. Rank hold ELDN as of Q1 2017.

  • Acrospire Investment Management reported no remaining Eledon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 287 Eledon Pharmaceuticals shares in Q1 2017, an estimated $46K.
  • Acrospire Investment Management first reported a position in Eledon Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Eledon Pharmaceuticals position peaked at $46K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.